SaNOtize’s key innovation is the development of solutions that locally release nitric oxide (NO) in concentrations with potential antimicrobial effects against viruses, bacteria, and fungi.

Nitric oxide is a molecule that naturally occurs in our bodies. For decades, it has been approved to treat “blue baby syndrome” in hospitals, delivered through pressurized gas cylinders and special inhalation delivery devices. While years of research had also demonstrated its antimicrobial properties, designing a platform to store and deliver it safely and conveniently enough for everyday use was a major challenge.

Recognizing the remarkable promise of NO as a topical antimicrobial and ready to tackle the design task, the founders of SaNOtize innovated novel technology to stabilize and deliver NO in precise doses at the site of infection. Their proprietary platform, Nitric Oxide Releasing Solution (NORS™), enables the molecule to be used as a therapeutically effective antimicrobial to treat respiratory and topical infections.

SaNOtize’s patented technology is giving rise to a pipeline of anti-infective products with the potential to improve the quality of life for millions. Using NORS, SaNOtize can develop gels, creams, and liquids to address a wide range of viral, bacterial, and fungal infections.